Latest Manufacturing News

Epsilon Healthcare has completed a $6.7 million sale and leaseback of its Southport manufacturing site, significantly reducing debt and securing long-term operational stability.

Prescient Therapeutics has raised $6.8 million through a Share Purchase Plan to fund the Phase 2 development of its novel cancer therapy PTX-100, while launching a discounted placement to sophisticated investors.

Diatreme Resources has formalised a negotiation framework with the Gulaal People, setting the stage for collaborative development of its Northern Silica Project while prioritising cultural heritage and community benefits.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Australian Rare Earths Limited (ASX, AR3) reports successful metallurgical testwork at its Koppamurra Rare Earths Project, producing 34kg of Mixed Rare Earth Oxide from heap leach solutions, paving the way for streamlined, cost-effective rare earth processing.

Alpha HPA Limited has kicked off major civil works for its HPA First Project Stage 2 while securing strong sales momentum in the semiconductor sector, supported by expanded Letters of Intent covering over 60% of Stage 2 capacity.

Clever Culture Systems advances its pharmaceutical market penetration with AstraZeneca’s full deployment and Novo Nordisk’s first order, while launching a new contact plate analysis module that doubles its APAS Independence system’s capabilities.

Imagion Biosystems has made significant progress towards filing an Investigational New Drug application for its MagSense® HER2 breast cancer imaging agent, receiving encouraging feedback from the FDA and preparing for a Phase 2 clinical trial.

Iondrive Limited advances its proprietary battery recycling technology with a pilot plant design, European consortium formation, and new e-waste initiatives, supported by significant grant funding.

Bannerman Energy reports robust progress on its Etango Uranium Project, achieving key construction milestones and securing A$85 million in fresh equity to fuel its path to a Final Investment Decision.

SomnoMed reports a robust Q4 FY25 with 25% revenue growth and a milestone of treating over 1 million patients, while gearing up for significant capacity expansion and clinical advancements.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.